OBJECTIVE: Patient-reported measures can quickly provide assessments of rheumatoid arthritis (RA) disease activity in the office setting and do not require a laboratory test or physician examination. The goal of our study was to establish the validity of patient-reported indices compared to the C-reactive protein-based Disease Activity Score (DAS28-CRP4). METHODS: Baseline and 1-year followup DAS28-CRP4 data were obtained from 740 RA subjects and were compared to indices (MDHAQ, CDAI, RAPID, RADAI, GAS) according to cyclic citrullinated peptide (CCP) status and change at 1 year. Pairwise correlations were calculated for each index. RESULTS: Among 740 subjects, mean age 57 years, disease duration 14 years, the CDAI (r = 0.84, Δ r = 0.80) and RAPID (r = 0.71, Δ r = 0.70) had the highest correlation with the DAS28-CRP4 scores at baseline and 1 year. These correlations were not influenced by CCP status, disease-modifying antirheumatic drug use, biologic use, or by disease duration. CONCLUSION: In RA, the CDAI and RAPID correlated well with the DAS28-CRP4. They may both be practical and informative in the care of patients in the office setting.
OBJECTIVE:Patient-reported measures can quickly provide assessments of rheumatoid arthritis (RA) disease activity in the office setting and do not require a laboratory test or physician examination. The goal of our study was to establish the validity of patient-reported indices compared to the C-reactive protein-based Disease Activity Score (DAS28-CRP4). METHODS: Baseline and 1-year followup DAS28-CRP4 data were obtained from 740 RA subjects and were compared to indices (MDHAQ, CDAI, RAPID, RADAI, GAS) according to cyclic citrullinated peptide (CCP) status and change at 1 year. Pairwise correlations were calculated for each index. RESULTS: Among 740 subjects, mean age 57 years, disease duration 14 years, the CDAI (r = 0.84, Δ r = 0.80) and RAPID (r = 0.71, Δ r = 0.70) had the highest correlation with the DAS28-CRP4 scores at baseline and 1 year. These correlations were not influenced by CCP status, disease-modifying antirheumatic drug use, biologic use, or by disease duration. CONCLUSION: In RA, the CDAI and RAPID correlated well with the DAS28-CRP4. They may both be practical and informative in the care of patients in the office setting.
Authors: Liana Fraenkel; Ellen Peters; Peter Charpentier; Blair Olsen; Lanette Errante; Robert T Schoen; Valerie Reyna Journal: Arthritis Care Res (Hoboken) Date: 2012-07 Impact factor: 4.794
Authors: Jeffrey R Curtis; Annette H van der Helm-van Mil; Rachel Knevel; Tom W Huizinga; Douglas J Haney; Yijing Shen; Saroja Ramanujan; Guy Cavet; Michael Centola; Lyndal K Hesterberg; David Chernoff; Kerri Ford; Nancy A Shadick; Max Hamburger; Roy Fleischmann; Edward Keystone; Michael E Weinblatt Journal: Arthritis Care Res (Hoboken) Date: 2012-12 Impact factor: 4.794
Authors: Ulrich A Walker; Ruediger B Mueller; Veronika K Jaeger; Robert Theiler; Adrian Forster; Patrick Dufner; Fabiana Ganz; Diego Kyburz Journal: Rheumatology (Oxford) Date: 2017-10-01 Impact factor: 7.580
Authors: Tim Pickles; Rhiannon Macefield; Olalekan Lee Aiyegbusi; Claire Beecher; Mike Horton; Karl Bang Christensen; Rhiannon Phillips; David Gillespie; Ernest Choy Journal: RMD Open Date: 2022-03